Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 7/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877370 | 1.00 | PGR (0.42) | PGRSLC22A12IMPDH2IMPDH1AR | |
| SCHEMBL4878791 | 0.79 | AR (0.50) | ARIDO1 | |
| SCHEMBL4878796 | 0.79 | AR (0.50) | ARIDO1 | |
| SCHEMBL22875049 | 0.72 | CCR6 (0.46) | — | |
| SCHEMBL10781954 | 0.68 | IDO1 (0.52) | SLC22A12IMPDH2IMPDH1ARIDO1 | |
| SCHEMBL3592333 | 0.68 | AR (0.62) | AR | |
| SCHEMBL20140157 | 0.67 | GRM5 (0.41) | — | |
| SCHEMBL16039783 | 0.66 | KDM4E (0.50) | — | |
| SCHEMBL16039781 | 0.66 | KDM4E (0.50) | — | |
| SCHEMBL24074639 | 0.65 | KMT2A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | claimed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | PGR 69/4885SLC22A12 530/4885IMPDH2 777/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | PGR 65/4885SLC22A12 525/4885IMPDH2 845/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | PGR 69/4885SLC22A12 530/4885IMPDH2 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.